Glycogen phosphorylase BB in acute coronary syndromes
-
Dirk Peetz
Abstract
The diagnosis of myocardial damage is preferably based on measurement of the cardiac-specific troponins. However, there is an emerging need for early, specific cardiac markers. One potential candidate is the glycogen phosphorylase BB isoenzyme (GPBB). We investigated the use of a new, commercially available GPBB ELISA assay in 61 patients presenting with an acute coronary syndrome (37 acute myocardial infarction, 24 unstable angina pectoris) in comparison to established cardiac markers such as troponin T, creatine kinase isoenzyme MB (CKMB) mass, and myoglobin. Blood samples were obtained on arrival, as well as 1, 2, 3, 4, 8, 12 and 24h later. GPBB plasma concentrations were elevated in 90.9% of patients 1h after onset of chest pain and increased to 100% at 4–5h. Within the first 6h, GPBB showed the highest sensitivity (95.5–100%) and high specificity (94–96%) compared to myoglobin (85–95% sensitivity) and CKMB mass (71.4–91.3% sensitivity). As expected, troponin T showed high specificity (100%) and sensitivity >95% later in the time course (≥3h). In un-stable angina pectoris patients, a very high rate of elevated GPBB was observed (93.9% at 3h) compared to myoglobin (66.7%). Cardiac troponin T and CKMB were only elevated in 33.8% and 55.0% of these patients, respectively. In conclusion, GPBB is a promising marker for the early diagnosis of acute coronary syndromes and could probably act as a marker of ischemia. However, further studies on specificity and development of a fast, automated assay are necessary before GPBB can be recommended as a routine diagnostic tool.
References
1. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959–69.10.1016/S0735-1097(00)00804-4Suche in Google Scholar
2. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, et al. Characteristics of an Albumin Cobalt Binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001; 47:464–70.10.1093/clinchem/47.3.464Suche in Google Scholar
3. Alhadi HA, Fox KA. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein. QJM 2004; 97:187–98.10.1093/qjmed/hch037Suche in Google Scholar
4. Rabitzsch G, Mair J, Lechleitner P, Noll F, Hofmann U, Krause EG, et al. Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 1995; 41:966–78.10.1093/clinchem/41.7.966Suche in Google Scholar
5. Entman ML, Bornet EP, Van Winkle WB, Goldstein MA, Schwartz A. Association of glycogenolysis with cardiac sarcoplasmic reticulum: II. Effect of glycogen depletion, deoxycholate solubilization and cardiac ischemia: evidence for a phorphorylase kinase membrane complex. J Mol Cell Cardiol 1977; 9:515–28.10.1016/S0022-2828(77)80367-2Suche in Google Scholar
6. Newgard CB, Hwang PK, Fletterick RJ. The family of glycogen phosphorylases: structure and function. Crit Rev Biochem Mol Biol 1989; 24:69–99.10.3109/10409238909082552Suche in Google Scholar PubMed
7. Kato K, Shimizu A, Kurobe N, Takashi M, Koshikawa T. Human brain-type glycogen phosphorylase: quantitative localization in human tissues determined with an immunoassay system. J Neurochem 1989; 52:1425–32.10.1111/j.1471-4159.1989.tb09189.xSuche in Google Scholar PubMed
8. Krause EG, Rabitzsch G, Noll F, Mair J, Puschendorf B. Glycogen phosphorylase isoenzyme BB in diagnosis of myocardial ischaemic injury and infarction. Mol Cell Biochem 1996; 160/161:289–95.10.1007/BF00240061Suche in Google Scholar PubMed
9. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24:28–66.Suche in Google Scholar
10. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23:1809–40.10.1053/euhj.2002.3385Suche in Google Scholar PubMed
11. Panteghini M. Acute coronary syndrome: biochemical strategies in the troponin era. Chest 2002; 122:1428–35.10.1378/chest.122.4.1428Suche in Google Scholar PubMed
12. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial in-farction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). http://www.acc.org/clinical/guidelines/unstable/unstable.pdf.Suche in Google Scholar
13. Jesse RL. Rationale for the early clinical application of markers of ischemia in patients with suspected acute coronary syndromes. In: Wu AH, editor. Cardiac markers, 2nd ed. Totowa, NJ: Humana Press, 2003:245–57.Suche in Google Scholar
14. Morrow DA, de Lemos JA, Sabatine MS, Antman EM. The search for a biomarker of cardiac ischemia. Clin Chem 2003; 49:537–9.10.1373/49.4.537Suche in Google Scholar
15. Wu AH, Morris DL, Fletcher DR, Apple FS, Christenson RH, Painter PC. Analysis of the Albumin Cobalt Binding (ACB) test as an adjunct to cardiac troponin I for the early detection of acute myocardial infarction. Cardiovasc Toxicol 2001; 1:147–51.10.1385/CT:1:2:147Suche in Google Scholar
16. Peeters RA, in't Groen MA, Veerkamp JH. The fatty acid-binding protein from human skeletal muscle. Arch Biochem Biophys 1989; 274:556–63.10.1016/0003-9861(89)90470-0Suche in Google Scholar
17. Sorichter S, Mair J, Koller A, Pelsers MM, Puschendorf B, Glatz JF. Early assessment of exercise induced skeletal muscle injury using plasma fatty acid binding protein. Br J Sports Med 1998; 32:121–4.10.1136/bjsm.32.2.121Suche in Google Scholar
18. Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51:810–24.10.1373/clinchem.2004.046292Suche in Google Scholar
19. Rabitzsch G, Mair J, Lechleitner P, Noll F, Hofmann V, Krause EG, et al. Isoenzyme BB of glycogen phosphorylase b and myocardial infarction. Lancet 1993; 341:1032–3.10.1016/0140-6736(93)91129-ASuche in Google Scholar
20. Setsuta K, Seino Y, Takahashi N, Ogawa T, Sasaki K, Harada A, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol 1999; 84:608–11.10.1016/S0002-9149(99)00391-4Suche in Google Scholar
21. Peetz D, Schutt S, Sucke B, Faldum A, Wandel E, Hafner G, et al. Prognostic value of troponin T, troponin I, and CK-MB mass in patients with chronic renal failure. Med Klin (Munich) 2003; 98:188–92.10.1007/s00063-003-1243-3Suche in Google Scholar
22. Byrick RJ. Fat embolism and postoperative coagulopathy. Can J Anaesth 2001; 48:618–21.10.1007/BF03016192Suche in Google Scholar PubMed
23. Backlund M, Lepantalo M, Toivonen L, Tuominen M, Tarkkil P, Pere P, et al. Factors associated with post-operative myocardial ischaemia in elderly patients undergoing major non-cardiac surgery. Eur J Anaesthesiol 1999; 16:826–33.10.1097/00003643-199912000-00003Suche in Google Scholar
24. Richter F, Bohme HJ, Hofmann E. Changes of glycogen phosphorylase isozyme pattern, in rat tissues during pre- and postnatal development. Biomed Biochim Acta 1988; 47:743–52.Suche in Google Scholar
25. Mair J. Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage. Clin Chim Acta 1998; 272:79–86.10.1016/S0009-8981(97)00254-4Suche in Google Scholar
©2005 by Walter de Gruyter Berlin New York
Artikel in diesem Heft
- Contents Volume 43, 2005
- Author Index
- Subject Index
- ProteinChips: the essential tools for proteomic biomarker discovery and future clinical diagnostics
- Protein profiling as a diagnostic tool in clinical chemistry: a review
- Protein biochip systems for the clinical laboratory
- Automation of biochip array technology for quality results
- SELDI-TOF-MS proteomics of breast cancer
- Protein microarrays for the diagnosis of allergic diseases: state-of-the-art and future development
- Separation of human serum proteins using the Beckman-Coulter PF2D™ system: analysis of ion exchange-based first dimension chromatography
- Rapid, accurate genotyping of alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 based on the use of denaturing HPLC
- APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals
- Simple PCR heteroduplex, SSCP mutation screening methods for the detection of novel catalase mutations in Hungarian patients with type 2 diabetes mellitus
- Glycogen phosphorylase BB in acute coronary syndromes
- Alteration in serum leptin correlates with alterations in serum N-telopeptide of collagen type I and serum osteocalcin during the progression of osteoporosis in ovariectomized rats
- Glycemic control in diabetes in three Danish counties
- Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells
- Buprenorphine detection in biological samples
- The effect of thyroid antibody positivity on reference intervals for thyroid stimulating hormone (TSH) and free thyroxine (FT4) in an aged population
- High-affinity antibodies in a new immunoassay for plasma tissue factor: reduction in apparent intra-individual variation
- Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex® Multiplex technology
- Sensitive immunoassays for the autoantibodies reacting against citrullinated carboxy-terminal telopeptides of type I and type II collagens in patients with rheumatoid arthritis
- Acknowledgement
Artikel in diesem Heft
- Contents Volume 43, 2005
- Author Index
- Subject Index
- ProteinChips: the essential tools for proteomic biomarker discovery and future clinical diagnostics
- Protein profiling as a diagnostic tool in clinical chemistry: a review
- Protein biochip systems for the clinical laboratory
- Automation of biochip array technology for quality results
- SELDI-TOF-MS proteomics of breast cancer
- Protein microarrays for the diagnosis of allergic diseases: state-of-the-art and future development
- Separation of human serum proteins using the Beckman-Coulter PF2D™ system: analysis of ion exchange-based first dimension chromatography
- Rapid, accurate genotyping of alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 based on the use of denaturing HPLC
- APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals
- Simple PCR heteroduplex, SSCP mutation screening methods for the detection of novel catalase mutations in Hungarian patients with type 2 diabetes mellitus
- Glycogen phosphorylase BB in acute coronary syndromes
- Alteration in serum leptin correlates with alterations in serum N-telopeptide of collagen type I and serum osteocalcin during the progression of osteoporosis in ovariectomized rats
- Glycemic control in diabetes in three Danish counties
- Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells
- Buprenorphine detection in biological samples
- The effect of thyroid antibody positivity on reference intervals for thyroid stimulating hormone (TSH) and free thyroxine (FT4) in an aged population
- High-affinity antibodies in a new immunoassay for plasma tissue factor: reduction in apparent intra-individual variation
- Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex® Multiplex technology
- Sensitive immunoassays for the autoantibodies reacting against citrullinated carboxy-terminal telopeptides of type I and type II collagens in patients with rheumatoid arthritis
- Acknowledgement
